HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Business Round-Up: Galenica Boosted By Deals, Alliance's Sales Rise, And Beiersdorf Relaunches Wound Care

Executive Summary

Latest EU business news: Galenica posts sales up in 2020 thanks to deals; Alliance Pharma's Consumer sales edge up despite COVID-19; and Beiersdorf is relaunching its wound care range with sustainability in mind.

You may also be interested in...



Alliance Pharma Grows In US With Amberen Menopause Supplement

UK-based Alliance Pharma has strengthened its US offering by acquiring Biogix and its Amberen menopause supplement.

Galenica Expands Swiss OTC Offering Through Hedoga Acquisition

Galenica has reinforced its position as the leading player in the Swiss OTC market through the acquisition of Hedoga Group,

J&J cuts Nizoral to focus on core lines

Johnson & Johnson (J&J) is offloading the rights to the Nizoral dandruff treatment in three separate deals as part of its strategy to divest non-core assets and focus on its larger Consumer brands.

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel